Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-05-24
2011-05-24
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S130100, C424S133100, C424S138100, C424S139100, C424S141100, C424S142100, C424S143100, C424S155100, C424S158100, C514S019400
Reexamination Certificate
active
07947653
ABSTRACT:
Cancer treatment with a combination of an Epidermal Growth Factor Receptor tyrosine kinase inhibitor and an Interleukin-6 inhibitor.
REFERENCES:
patent: 2006/0211060 (2006-09-01), Haley et al.
patent: 2008/0066741 (2008-03-01), LeMahieu et al.
patent: 2008/0234264 (2008-09-01), Bell et al.
patent: 2008/0312260 (2008-12-01), Haley et al.
patent: 2009/0022726 (2009-01-01), Zaki et al.
patent: 2009/0238825 (2009-09-01), Kovacevich et al.
patent: 2009/0286850 (2009-11-01), Shaaban et al.
patent: 2009/0297436 (2009-12-01), Garcia-Martinez et al.
patent: 2009/0297513 (2009-12-01), Garcia-Martinez et al.
patent: 2010/0129357 (2010-05-01), Garcia-Martinez et al.
patent: 2010/0135983 (2010-06-01), Hyde et al.
patent: 2010/0137246 (2010-06-01), Hyde et al.
patent: 2010/0143294 (2010-06-01), Smith
patent: 2010/0150936 (2010-06-01), Edvardsen et al.
patent: WO 2008/154927 (2008-12-01), None
patent: WO 2010/065078 (2010-06-01), None
Faller et al., 2009, Biologics: Targets & Therapy 3:419-428.
Yao et al., 2010, PNAS USA 107:15535-15540.
“Supplementary Figures” received Feb. 25, 2011, pp. 1-34.
Catlett-Falcone et al., “Constitutive Activation of Stat3 Signaling Conferes Resistance to apoptosis in Human U266 Myeloma Cells,”Immunity10:105-115 (1999).
Colomiere et al., “Cross Talk of Signals Between EGFR and IL-6R Through JAK2/STAT3 Mediate Epithelial-Mesenchymal Transition in Ovarian Carcinomas,”British Journal of Cancer100:134-144 (2009).
Gao et al., “Mutations in the EGFR Kinase Domain Mediate STAT3 Activation Via Il-6 Production in Human Lung Adenocarcinomas,”The Journal of Clinical Investigation117:3846-3856 (2007).
Grivennikov and Karin, “Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?,”Cancer Cells13:7-9 (2008).
Haura et al., “Activated Epidermal Growth Factor Receptor-Stat-3 Signaling Promotes Tumor Survival In Vivo in Non-Small Cell Lung Cancer,”Clinical Cancer Research11:8288-8294 (2005).
Ji et al., “Epidermal Growth Factor Receptor Variant III Mutations in Lung Tumorigenesis and Sensitivity to Tyrosine Kinase Inhibitors,”PNAS103:7817-7822 (2006).
Lee et al., “Epigenetic Modification of SOCS-1 Differentially Regulates STAT3 Activation in Response to Interleukin-6 Receptor and Epidermal Growth Factor Receptor Signaling Through JAk and/or MEK in Head and Neck Squamous Cell Carcinomas,”Mol. Cancer Ther. 5(1):8-19 (2006).
Lynch et al., “Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib,”The New England Journal of Medicine350(21):2129-2139 (2004).
Pao et al., “Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is Associated with a Second Mutation in the EGFR Kinase Domain,” PLOS Medicine 2:0225-0235 (2005).
Sansone et al., “IL-6 Triggers Malignant Features in Mammospheres from Human Ductal Breast Carcinoma and Normal Mammary Gland,”The Journal of Clinical Investigation117(12):3988-4002 (2007).
Schafer and Brugge, “IL-6 Involvement in Epithelial Cancers,”The Journal of Clinical Investigation117(12):3660-3663 (2007).
Trikha et al., “Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence,”Clinical Cancer Research9:4653-4665 (2003).
Wang et al., “Current and Potential Inflammation Targeted Therapies in Head and Neck Cancer,”Elsevier9:389-395 (2009).
Fenoglio Silvia
Lindsted Trine
Sordella Raffaella
Cold Spring Harbor Laboratory
Kemmerer Elizabeth C.
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods for treating epidermal growth factor receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating epidermal growth factor receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating epidermal growth factor receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630688